You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Whispering Gallery Mode Devices for the Rapid Detection of Pan-Filoviruses

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Project Summary Filoviruses, including the Ebola viruses, Marburg viruses, and Cueva virus, are a class of pathogens with enormous health implications. Filoviruses have been implicated in numerous outbreaks in Africa, including the ongoing outbreak in the Democratic Republic of Congo (DRC), potential risk as an agent of bioterrorism, and the potential risk of transmission to non-endemic countries ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections

    SBC: EXBAQ LLC            Topic: NIAID

    PROJECT SUMMARY According to the CDC, 550,000 Healthcare Associated Infections (HAIs) occur per year in the US, costing ~$100 billion and killing tens of thousands of patients. Reducing HAIs is a top priority of the US DHHS and NIH and experts have called for novel strategies including vaccination to achieve this goal.ExBaq was founded by scientists and business colleagues who have spent years stu ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Feasibility of mHealth technology-enabled service for remote observed therapy of methadone and COVID-19 screening for patients in an opioid treatment program

    SBC: Emocha Mobile Health Inc.            Topic: NIDA

    PROJECT SUMMARY Methadone remains a cornerstone of treatment for opioid use disorders (OUD). Daily or frequent supervised treatment with visual confirmation of ingestion (directly-observed therapy or “DOT”), is the standard of care for methadone treatment in federally licensed opioid treatment programs (OTPs) in the United States. DOT ensures adherence and mitigates the risk of medication pois ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical proof of concept validation of a novel endoscopic treatment for urethral stricture disease

    SBC: Celeflux LLC            Topic: 400

    PROJECT SUMMARY/ABSTRACT CeleFlux is developing a medical device which enables urologists to provide long-lasting, minimally invasive urethral reconstruction to treat male urethral stricture - via endoscopic delivery of a temporary tissue graft implant. Urethral stricture disease progressively narrows the urethral lumen, similar to a band of scar tissue. This results in painful and frequent urinat ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the community

    SBC: EPERTURE LLC            Topic: NIA

    Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Feelix @ Home: Testing and optimization of a smart stethoscope for home use to monitor changes in lung status of individuals with chronic conditions

    SBC: SONAVI LABS INC            Topic: NHLBI

    Project SummaryThe goal of this project is to further develop an existing smart stethoscope in order to be capable of monitoring pediatric patients at home who suffer from asthma as well as adults with COPD. Lung diseases impose a serious burden on healthcare systems, individuals and governments. The World Health Organization (WHO) found that chronic obstructive pulmonary disease (COPD) and lower ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Hsp90 beta-selective inhibitors as safer anti-cancer agents

    SBC: Grannus Therapeutics LLC            Topic: NCI

    Abstract The 90 kD heat shock proteins (Hsp90) are molecular chaperones that are responsible for the folding of select proteins, many of which are directly associated with cancer progression. Consequently, inhibition of the Hsp90 protein folding machinery results in a combinatorial attack on numerous oncogenic pathways. Seventeen small molecule inhibitors of Hsp90 have entered clinical trials for ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. OBJECTIVE HOME MANAGEMENT OF PEDIATRIC ASTHMA EXACERBATION USING MOBILE TECHNOLOGY AND MACHINE LEARNING

    SBC: AUSCULTECH DX LLC            Topic: 600

    PROJECT SUMMARY Asthma is the most common chronic pediatric disease in the United States, affecting 6.2 million or 1 in 12 children. Despite advances in the management of childhood asthma, asthma exacerbation results in approximately 550,000 emergency department (ED) visits, 80,000 hospitalizations, and hundreds of premature deaths each year. Early symptoms of asthma exacerbation, especially in ch ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Monoclonal antibodies targeting novel sites of vulnerability in marburg virus glycoprotein

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    Filoviruses, consisting of two major virus families including the ebolaviruses and marburgviruses (MARV and RAVV), cause periodic outbreaks of severe viral hemorrhagic fever with mortality rates as high as 90%. Since it is difficult to predict the species that would dominate future outbreaks, development of broadly protective therapeutics to prevent and manage future filovirus outbreaks is of high ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Aminonaphthyridine compounds as potential therapeutics for lung and thyroid cancers

    SBC: KinaRx, LLC            Topic: 102

    Over the past three decades a growing number of cancer-driving protein kinases have been successfully targeted as reflected in the approval of 49 kinase inhibitors by the Food and Drug Administration (FDA). Recent approval of the first tyrosine kinase inhibitor (Larotrectinib) for treatment of any cancer bearing mutation in neurotrophic receptor kinase validated a novel paradigm of precision targe ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government